Prenatal pertussis coverage slips again as London drives the national decline
England’s prenatal pertussis vaccination programme continued to cover most eligible pregnant women in early 2022, but the latest surveillance data show another step down in uptake. Quarterly coverage for women delivering from January to March 2022 averaged 64.0%, while annual coverage for April 2021 to March 2022 reached 64.7%. Both figures sit below the comparable periods in the previous two years, continuing a downward trend that matters because maternal immunisation remains the main bridge of protection for newborns before routine infant vaccination begins at 8 weeks of age.
The drop is not subtle. Quarterly coverage was 2.8 percentage points lower than in the same quarter of 2020 to 2021 and 8.3 points lower than in the same quarter of 2019 to 2020. On the annual measure, coverage fell 3.1 percentage points from 2020 to 2021 and 5.8 points from 2019 to 2020, when it stood at 70.5%.
Why maternal pertussis vaccination still carries heavy clinical weight
Pertussis is not a seasonal nuisance in early infancy; it can be lethal before a baby is old enough to respond fully to its own primary immunisation series. The UK programme is built on a simple biological principle: vaccinating the mother during pregnancy allows protective antibodies to cross the placenta and circulate in the infant during the highest-risk window. In practical terms, maternal vaccination is meant to reduce disease, hospitalisation, and deaths in infants too young for direct active protection.
The policy structure also reflects timing. Pregnant women became eligible from 16 weeks’ gestation after JCVI review, although operational guidance recommends offering vaccination from around 20 weeks, after the foetal anomaly scan. Earlier access increases the number of opportunities to vaccinate during antenatal care, but the programme still depends on consistent delivery across maternity and primary care settings.
During the COVID-19 pandemic, that delivery faced strain across many preventive services. Routine vaccination was prioritised, including time-sensitive maternal vaccines, yet the current data show that coverage did not recover to pre-pandemic levels. The persistence of lower uptake suggests the barrier is not a temporary reporting artifact. It is a service delivery problem with direct neonatal consequences.
National coverage held near two-thirds, but the monthly pattern stayed flat
The quarterly range was narrow: 64.3% in January and 63.4% in March. That modest month-to-month spread suggests the problem was not a sudden collapse in one reporting point but a sustained shortfall across the quarter. In surveillance terms, the plateau matters as much as the decline, because it indicates a stable level of missed opportunities rather than a single disrupted month.
All GP IT suppliers submitted data for the period, and national GP practice participation remained high at 96.3% in January, 96.7% in February, and 96.9% in March. Data completeness was therefore strong enough to support confidence in the direction of travel. The dataset was drawn automatically through ImmForm from participating GP systems, with validation steps to identify anomalies and review completeness. Accurate extraction still depends on clean clinical records, including the delivery date, the date of pertussis-containing vaccination at or after week 16, and stillbirth or miscarriage coding where relevant.
London accounted for much of the downward pressure
The clearest regional signal came from London NHS Commissioning Region, where coverage in March 2022 was 12.9 percentage points lower than in March 2020. That regional fall largely explains the national decline. When one region moves so far below its earlier performance, it can pull the entire country’s average down even if other areas remain comparatively stable.
The pattern raises familiar questions about access, appointment availability, continuity of maternity care, and the ease with which pregnant women can move between services. Antenatal vaccination works best when it is embedded in routine care rather than treated as an optional add-on. Any break in referral pathways, any missed booking visit, and any uncertainty about which team is responsible can translate into a missed dose.
The public health implication is immediate: lower maternal coverage means fewer newborns receive antibody-derived protection during the most vulnerable weeks of life. Pertussis spreads easily, and infants under 3 months remain the group most likely to experience severe outcomes.
Surveillance quality remains strong, but the trend still points in the wrong direction
Annual coverage for 2021 to 2022 was calculated by summing the 12 monthly numerators and denominators, rather than by separate annual extraction. That approach allows a straightforward assessment of year-long delivery performance using the same monthly coding structure. Geographic comparisons were made using 2019 NHS England configurations, while CCGs were omitted because of changes in NHS geography and the abolition of CCGs from 1 July 2022.
The surveillance framework is robust enough to track change, and it has now done so across several years of prenatal pertussis coverage in England. What it reveals is a programme that remains established but is still underperforming relative to earlier years. The decline is not catastrophic, yet it is large enough to matter clinically, especially when the target population includes both pregnant women and infants who cannot yet rely on their own immune response.
A coverage rate in the mid-60s still leaves a substantial minority of eligible women unvaccinated. For a maternal immunisation programme designed to create a protective buffer before infant vaccination starts, every percentage point lost represents another set of newborns entering their first weeks of life with less passive protection.
Delivery during pregnancy remains the pressure point
The programme’s structure makes timing and workflow central. Vaccination is eligible from week 16, ideally offered around week 20, and may be delivered in general practice or selected maternity services. Those options should increase access, yet they also require coherent coordination across settings. In antenatal care, where multiple preventive interventions compete for attention, a vaccine can be missed simply because it is not offered at the right visit or the record is not updated correctly.
The broader epidemiology helps explain why this is consequential. Pertussis activity has historically affected all age groups, with the most severe burden falling on very young infants. The maternity programme exists to close the gap between maternal susceptibility and infant active immunisation. When uptake slips, that gap widens again.
The data leave several practical questions unresolved: which service barriers were most responsible for the London decline, whether the reduced coverage reflects persistent post-pandemic disruption or a new access problem, and how quickly performance can be restored to earlier levels. Those questions will matter more than any single quarter’s figure if the trend continues into the next reporting cycle.